Latest News

Analysts Expect InMode Ltd. (NASDAQ:INMD) to Post $0.39 Earnings Per Share

Shares of InMode Ltd. (NASDAQ:INMD) have been given an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Brokers have set a one year consensus price target of $32.50 for the company and are expecting that the company will post $0.39 EPS for the current quarter, according to Zacks. Zacks has also given InMode an industry rank of 104 out of 255 based on the ratings given to its competitors.

A number of analysts have weighed in on the stock. Barclays raised their target price on shares of InMode from $27.00 to $45.00 and gave the company an “overweight” rating in a research report on Wednesday. Robert W. Baird restated an “outperform” rating and issued a $45.00 target price (up previously from $27.00) on shares of InMode in a research report on Wednesday. UBS Group assumed coverage on shares of InMode in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $28.00 target price on the stock. Canaccord Genuity assumed coverage on shares of InMode in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of InMode from a “hold” rating to a “strong-buy” rating and set a $45.00 target price on the stock in a research report on Friday.

InMode stock traded down $1.17 during trading hours on Tuesday, hitting $40.44. The company had a trading volume of 1,335,000 shares, compared to its average volume of 997,418. InMode has a one year low of $13.06 and a one year high of $43.64. The company has a quick ratio of 3.89, a current ratio of 4.23 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average is $27.84.

InMode (NASDAQ:INMD) last issued its earnings results on Tuesday, November 5th. The healthcare company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.13. The company had revenue of $40.01 million during the quarter, compared to analyst estimates of $35.74 million. During the same quarter in the prior year, the business earned $0.26 EPS. The business’s quarterly revenue was up 57.4% on a year-over-year basis. Equities analysts anticipate that InMode will post 1.38 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. Optimum Investment Advisors bought a new position in shares of InMode during the third quarter valued at $28,000. Patriot Financial Group Insurance Agency LLC bought a new position in shares of InMode during the third quarter valued at $32,000. Tower Research Capital LLC TRC bought a new position in shares of InMode during the third quarter valued at $43,000. Steward Partners Investment Advisory LLC bought a new position in shares of InMode during the third quarter valued at $122,000. Finally, D.A. Davidson & CO. bought a new position in shares of InMode during the third quarter valued at $273,000. 0.55% of the stock is owned by hedge funds and other institutional investors.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.

Further Reading: What is the Moving Average Convergence Divergence (MACD) oscillator?

Get a free copy of the Zacks research report on InMode (INMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *